| 0.3 -0.009 (-2.88%) | 04-25 09:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.44 | 1-year : | 0.51 |
| Resists | First : | 0.38 | Second : | 0.44 |
| Pivot price | 0.34 |
|||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.3  |
MA(20) : | 0.35 |
| MA(100) : | 0.48 |
MA(250) : | 0.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15.7 |
D(3) : | 15.9 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 1.25 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QLGN ] has closed above bottom band by 29.2%. Bollinger Bands are 32.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.32 - 0.32 | 0.32 - 0.32 |
| Low: | 0.29 - 0.29 | 0.29 - 0.29 |
| Close: | 0.31 - 0.31 | 0.31 - 0.31 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Wed, 10 Apr 2024
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research ... - GlobeNewswire
Tue, 09 Apr 2024
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in ... - GlobeNewswire
Tue, 27 Feb 2024
Qualigen Therapeutics Secures Investment and Expands Financing Options - TipRanks.com - TipRanks
Tue, 07 Nov 2023
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of ... - Yahoo Finance
Wed, 27 Sep 2023
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 - GlobeNewswire
Thu, 17 Aug 2023
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 80 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -2.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.39 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -67 % |
| Return on Equity (ttm) | -374.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | -0.8 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|